Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : South Korea's SK Bioscience in deal with AstraZeneca on vaccine

07/21/2020 | 03:26am EST
FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the NYSE in New York

South Korea's SK Bioscience has agreed to manufacture AstraZeneca's experimental COVID-19 vaccine to help the British company build global supplies of the vaccine that has shown promise against the new coronavirus, it said on Tuesday.

Data on Monday showed that the vaccine, jointly developed by AstraZeneca and the University of Oxford, produced an immune response in early-stage clinical trials.

AstraZeneca has signed agreements with governments around the world to supply the vaccine should it prove effective and gain regulatory approval. It has already signed deals to produce and supply over 2 billion doses of the shot, with 300 million doses earmarked for the United States.

SK Bioscience, a unit of SK Chemicals, said it will start producing undiluted solutions of the vaccine after discussing production plans with AstraZeneca.

The manufacturing contract, which begins this month, will last until early next year and could be extended depending on AstraZeneca's success in development of the vaccine, SK said.

South Korea's health ministry arranged discussions between the two companies and will also begin discussions with AstraZeneca to introduce the vaccine to the country, it said.

The World Health Organization's chief scientist has said the vaccine, called AZD1222, is the leading candidate in a global race to halt a pandemic that has killed more than 600,000.

AZD1222 was developed by Oxford University and licensed to AstraZeneca, which has put it into large-scale, late-stage trials to test its efficacy.

(Reporting by Sangmi Cha; Editing by Jason Neely and Tom Hogue)

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 1.66% 7777 Delayed Quote.6.19%
SK CHEMICALS CO.,LTD. -2.03% 410500 End-of-day quote.4.59%
All news about ASTRAZENECA PLC
04:52pChina Overtakes U.S. as World's Leading Destination for Foreign Direct Invest..
03:28pASTRAZENECA : Ecuador approves use of AstraZeneca vaccine for COVID-19
01:23pChina Overtakes U.S. as World's Leading Destination for Foreign Direct Invest..
01:14pChina Overtakes U.S. as World's Leading Destination for Foreign Direct Invest..
11:36aPFIZER : UK vaccination drive expands as virus toll nears 100,000
10:11aASTRAZENECA : Italy to take legal action on COVID vaccine delays to get doses
09:00aASTRAZENECA : Italy to take legal action over COVID vaccine delays to secure dos..
05:24aASTRAZENECA : EU says it will make vaccine companies respect supply contracts - ..
03:21aASTRAZENECA : India to give homegrown vaccine in seven more states this week
01/23THE LATEST : Chicago opens restaurants, some bars with limits
More news
Financials (USD)
Sales 2020 26 404 M - -
Net income 2020 2 955 M - -
Net Debt 2020 13 238 M - -
P/E ratio 2020 42,5x
Yield 2020 2,65%
Capitalization 140 B 139 B -
EV / Sales 2020 5,79x
EV / Sales 2021 4,98x
Nbr of Employees 70 600
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Average target price 126,47 $
Last Close Price 106,39 $
Spread / Highest target 46,7%
Spread / Average Target 18,9%
Spread / Lowest Target -15,2%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON3.92%430 552
ROCHE HOLDING AG3.06%308 615
NOVARTIS AG2.73%220 726
MERCK & CO., INC.-1.00%204 882
PFIZER INC.-0.71%203 159